In summary, current evidence indicates that Gal-3 serves both as a biomarker and as potential mediator of diabetic micro- and macrovascular complications, underscoring its relevance in risk stratification and its potential as a therapeutic target in diabetes management. The gene discussed is LGALS3; the disease is diabetes mellitus.